Individualized therapy for non-small cell lung cancer

A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands)·2013

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).

Annals of oncology : official journal of the European Society for Medical Oncology·2013

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2012

Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.

Lung cancer (Amsterdam, Netherlands)·2012

Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).

Cancer treatment reviews·2011

Brief Report on Sociodemographic Patterns of Lung Cancer in Individuals Who Never Smoked.

Clinical lung cancer·2026

Incidence of Radiation Pneumonitis Following EGFR-TKI Combined With Thoracic Radiotherapy in Unresectable Stage III or IV Non-Small-Cell Lung Cancer: A Systematic Review and Meta-analysis.

Clinical lung cancer·2026

Trends in Surgical Management of Early-stage Small Cell Lung Cancer.

Clinical lung cancer·2026

Impact of Zip-Based Social Determinants on Textbook Outcomes and Survival of Resected Early-Stage NSCLC.

Clinical lung cancer·2026

Semiconductor FDG PET/CT for Preoperative Identification of Grade 3 Invasive Nonmucinous Adenocarcinoma.

Clinical lung cancer·2026

Streamlining the Frequency, Conduct, and Location of Assessments in Registrational Lung Cancer Clinical Trials for Supplemental Applications: Recommendations of a LUNGevity Foundation Multistakeholder Working Group.

Clinical lung cancer·2026

Chemical Bond-Orchestrated Energy Depletion to Augment Lung Cancer Chemo-Immunotherapy.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Buddy Wire-Augmented Intravascular Lithotripsy in Refractory Calcified Coronary Lesions: A Five-Case Series.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate for dual chemotherapeutic and antibacterial targeting in the tumor microenvironment.

Biomedical microdevices·2026

Conservative and surgical treatment of wrist osteoarthritis: a systematic review.

Archives of orthopaedic and trauma surgery·2026

The pre-treatment tumor microenvironment immune status determines Bacillus Calmette-Guerin immunotherapy response in early-stage bladder cancer.

Cancer immunology research·2026

Related Experiment Videos

Individualized therapy for non-small cell lung cancer

Related Concept Videos

A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer.

A multicenter phase II study of cetuximab in combination with chest radiotherapy and consolidation chemotherapy in patients with stage III non-small cell lung cancer.

Identifying the target NSCLC patient for maintenance therapy: an analysis from a placebo-controlled, phase III trial of maintenance pemetrexed (H3E-MC-JMEN).

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer.

Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab.

Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).

Brief Report on Sociodemographic Patterns of Lung Cancer in Individuals Who Never Smoked.

Incidence of Radiation Pneumonitis Following EGFR-TKI Combined With Thoracic Radiotherapy in Unresectable Stage III or IV Non-Small-Cell Lung Cancer: A Systematic Review and Meta-analysis.

Trends in Surgical Management of Early-stage Small Cell Lung Cancer.

Impact of Zip-Based Social Determinants on Textbook Outcomes and Survival of Resected Early-Stage NSCLC.

Semiconductor FDG PET/CT for Preoperative Identification of Grade 3 Invasive Nonmucinous Adenocarcinoma.

Streamlining the Frequency, Conduct, and Location of Assessments in Registrational Lung Cancer Clinical Trials for Supplemental Applications: Recommendations of a LUNGevity Foundation Multistakeholder Working Group.

Chemical Bond-Orchestrated Energy Depletion to Augment Lung Cancer Chemo-Immunotherapy.

PROTAC-Engineered Protein/DNA Nanoantigen is a Potent Booster for Dendritic Cell Vaccines in Cancer Immunotherapy.

Buddy Wire-Augmented Intravascular Lithotripsy in Refractory Calcified Coronary Lesions: A Five-Case Series.

Poly(2-oxazoline) micelles for co-delivery of paclitaxel and metronidazole benzoate for dual chemotherapeutic and antibacterial targeting in the tumor microenvironment.

Conservative and surgical treatment of wrist osteoarthritis: a systematic review.

The pre-treatment tumor microenvironment immune status determines Bacillus Calmette-Guerin immunotherapy response in early-stage bladder cancer.

Related Experiment Videos

Individualized therapy for non-small cell lung cancer

Related Concept Videos

Related Articles